DK1966162T3 - Pyrimidinderivater - Google Patents

Pyrimidinderivater Download PDF

Info

Publication number
DK1966162T3
DK1966162T3 DK06831747.8T DK06831747T DK1966162T3 DK 1966162 T3 DK1966162 T3 DK 1966162T3 DK 06831747 T DK06831747 T DK 06831747T DK 1966162 T3 DK1966162 T3 DK 1966162T3
Authority
DK
Denmark
Prior art keywords
diamine
pyrimidine
methylamino
azetidin
inhibitors
Prior art date
Application number
DK06831747.8T
Other languages
English (en)
Inventor
Andrew Simon Bell
Charlotte Alice Louise Lane
Charles Eric Mowbray
Matthew Duncan Selby
Nigel Alan Swain
David Howard Williams
Original Assignee
Ziarco Pharma Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ziarco Pharma Ltd filed Critical Ziarco Pharma Ltd
Application granted granted Critical
Publication of DK1966162T3 publication Critical patent/DK1966162T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/48—Two nitrogen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/16—Central respiratory analeptics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/50—Three nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D497/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having oxygen and sulfur atoms as the only ring hetero atoms
    • C07D497/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having oxygen and sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D497/08—Bridged systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Immunology (AREA)
  • Urology & Nephrology (AREA)
  • Pain & Pain Management (AREA)
  • Epidemiology (AREA)
  • Dermatology (AREA)
  • Rheumatology (AREA)
  • Vascular Medicine (AREA)
  • Reproductive Health (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Otolaryngology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Endocrinology (AREA)
  • Biomedical Technology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Virology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)

Claims (13)

1. Forbindelse af formlen I:
eller et farmaceutisk og/eller veterinært acceptabelt salt eller solvat deraf, hvor: R1 er Ci-ealkyl, C3-7cycloalkyl-Co-6alkyl- eventuelt substitueret med methyl, alkoxyalkyl indeholdende 3 til 8 carbonatomer, het-Co-ealkyl-, CF3-Ci.6alkyl-, CF3OC2-3alkyl- eller Ci-6hydroxyalkyl; R3 og R2 danner sammen med det nitrogenatom, hvortil de er bundet, en 4 til 8 leddet ikke-aromatisk heterocyclisk gruppe, som eventuelt indeholder ét eller flere yderligere heteroatomer eller grupper uafhængigt valgt blandt N, O, S, S(O) og S(0)2, hvor den heterocycliske gruppe er eventuelt en forbundet bicyclisk gruppe, en spiro-bicyclisk gruppe eller er eventuelt forbundet med en 3-, 4-, 5- eller 6- leddet carbocyclisk gruppe eller en 4-, 5- eller 6-leddet heterocyclisk gruppe, som indeholder i det mindste ét ringelement uafhængigt valgt blandt N, O, S, S(O) og S(0)2, og hvor ringsystemet som helhed eventuelt er substitueret med én eller flere substituenter uafhængigt valgt blandt Ci^alkyl, NR6R7, (CH2)aC3-7cycloalkyl, alkoxyalkyl indeholdende 2 til 8 carbonatomer, (CH2)bhet1, (CH2)cCF3, (CH2)yOCF3, (CH2)daryl og Ci-6hydroxyalkyl, forudsat at ringsystemet som helhed indeholder i det mindste to nitrogenatomer eller indeholder ét nitrogenatom og er substitueret med en gruppe, som indeholder i det mindste ét nitrogenatom; R4 er H; R5 er H eller NH2; R6 og R7 er hver uafhængigt valgt blandt H, Ci-6alkyl og (CH2)jC3-7cycloalkyl; eller R6 og R7 danner, sammen med det nitrogenatom, hvortil de er bundet, en 4, 5 eller 6 leddet heterocyclisk gruppe; R8 er H; aryl er phenyl eventuelt substitueret med én eller flere grupper uafhængigt valgt blandt Ci-salkyl, Ci-ealkoxy, OH, halogen, CF3, CHF2, OCF3, OCHF2, SCF3, hydroxy-Ci-6alkyl, Ci-4alkoxy-Ci-6alkyl, Ci^alkyl-S-Ci^alkyl, CF2CF3, CH2CF3, CF2CH3, C(0)NR13R14, C3-8cycloalkyl, C3-7cycloalkyl-Ci^alkyl, C3-7cycloalkyl-Ci-4alkoxy, R13 og R14 er hver især uafhængigt valgt blandt H, Ci-6alkyl og (CH2)mC3-7cycloalkyl; eller R13 og R14, sammen med det nitrogenatom, hvortil de er bundet, danner en 4, 5 eller 6 leddet heterocyclisk gruppe; a, b, c, d, j og m er hver især uafhængigt valgt blandt er hver især uafhængigt valgt blandt 0, 1,2 og 3; y er uafhængigt valgt blandt 1,2 og 3; het er 4 til 8 leddet ikke-aromatisk heterocyclisk gruppe, som indeholder i det mindste ét heteroatom eller heterogruppe uafhængigt valgt blandt N, O, S, S(O) og S(0)2, hvor den heterocycliske gruppe eventuelt er en forbundet bicyclisk gruppe eller eventuelt er forbundet med en 3-, 4-, 5- eller 6-leddet carbocyclisk gruppe eller en 4-, 5- eller 6-leddet heterocyclisk gruppe, som indeholder i det mindste ét ringelement uafhængigt valgt blandt N, O, S, S(O) og S(0)2, og hvor ringsystemet som helhed eventuelt er substitueret med én eller flere substituenter uafhængigt valgt blandt Ci-ealkyl, NR6R7, (CH2)aC3-7cycloalkyl, alkoxyalkyl indeholdende 2 til 8 carbonatomer, (CH2)bhet1, (CH2)cCF3, (CH2)yOCF3, (CH2)daryl og Ci-6hydroxyalkyl; og het1 er en aromatisk eller ikke-aromatisk 4-, 5- eller 6-leddet heterocyclus, som indeholder i det mindste ét N, O eller S heteroatom, eventuelt forbundet med en 4-, 5-eller 6-leddet carbocyclisk gruppe eller en anden 4-, 5- eller 6-leddet heterocyclus, som indeholder i det mindste ét N, O eller S heteroatom.
2. Forbindelse ifølge krav 1, eller et farmaceutisk og/eller veterinært acceptabelt salt eller solvat deraf, hvor R1 er C^cycloalkyl-Co-ealkyl-, eventuelt substitueret med methyl.
3. Forbindelse ifølge krav 1 eller krav 2, eller et farmaceutisk og/eller veterinært acceptabelt salt eller solvat deraf, hvor R2 og R3 sammen med det nitrogenatom, hvortil de er bundet, danner en gruppe valgt blandt følgende ringsystemer:
hvor ringsystemet som helhed kan være substitueret med én eller flere Ci^alkyl eller (CH2)aC3-7cycloalkylgrupper.
4. Forbindelse ifølge krav 3 eller et farmaceutisk og/eller veterinært acceptabelt salt eller solvat deraf, hvor R6 og R7 uafhængigt er valgt blandt H eller CH3.
5. Forbindelse ifølge krav 1, eller et farmaceutisk og/eller veterinært acceptabelt salt eller solvat deraf, hvilken forbindelse er valgt blandt /\/Mcyclopropylmethyl)-6-r(3R)-3-(methvlamino)DvnOlidin-1-vllDvrimidin-2,4-diamin, A/4-(cyclopropylmethyl)-6-[(3R)-3-(methylamino)pyrrolidin-1-yl]pyrimidin-2,4-diamin- tartrat, N4-isobutyl-6-[(3R)-3-(methylamino)pyrrolidin-1-yl]pyrimidin-2,4-diamin, N4-(2,2-dimethylpropyl)-6-[(3R)-3-(methylamino)pyrrolidin-1-yl]pyrimidin-2,4-diamin, N-isobutyl-6-[(3R)-3-(methylamino)pyrrolidin-1-yl]pyrimidin-4-amin, N-(cyclopropylmethyl)-6-[(3R)-3-(methylamino)pyrrolidin-1-yl]pyrimidin-4-amin, N4-(2,2-dimethylpropyl)-6-[(4aR*,7aR*)-octahydro-6H-pyrrolo[3,4-b]pyridin-6- yl]pyrimidin-2,4-diamin, N4-cyclopropyl-6-[(4aR*,7aR*)-octahydro-6H-pyrrolo[3,4-b]pyridin-6-yl]pyrimidin-2,4- diamin, N4-cyclobutyl-6-[(4aR*,7aR*)-octahydro-6H-pyrrolo[3,4-b]pyridin-6-yl]pyrimidin-2,4- diamin, N4-(2,2-dimethylpropyl)-6-[3-(methylamino)azetidin-1-yl]pyrimidin-2,4-diamin, 6-(3-methylamino-azetidin-1-yl)-N4-(3,3,3-trifluor-propyl)-pyrimidin-2,4-diamin, N4-cyclopropylmethyl-6-(3-methylamino-azetidin-1-yl)-pyrimidin-2,4-diamin, N4-(3,3-dimethyl-butyl)-6-(3-methylamino-azetidin-1-yl)-pyrimidin-2,4-diamin, N4-cyclopentylmethyl-6-(3-methylamino-azetidin-1-yl)-pyrimidin-2,4-diamin, N4-isobutyl-6-[3-(methylamino)azetidin-1-yl]pyrimidin-2,4-diamin, 6-[3-(methylamino)azetidin-1-yl]-N4-propylpyrimidin-2,4-diamin, N4-(2,2-dimethylpropyl)-6-[(3R)-3-methylpiperazin-1-yl]pyrimidin-2,4-diamin, N4-ethyl-6-(4-methylpiperazin-1-yl)pyrimidin-2,4-diamin, N4-(cyclopropylmethyl)-6-(4-methylpiperazin-1-yl)pyrimidin-2,4-diamin, 6-[3-(methylamino)azetidin-1-yl]-N4-(2-methylbutyl)pyrimidin-2,4-diamin, N4-butyl-6-[3-(methylamino)azetidin-1-yl]pyrimidin-2,4-diamin, 6-[(3R)-3-(methylamino)pyrrolidin-1-yl]-N4-(2-methylcyclopropyl)pyrimidin-2,4-diamin, N4-isobutyl-6-(4-methyl-1,4-diazepan-1-yl)pyrimidin-2,4-diamin, N4-(cyclopropylmethyl)-6-(3-pyrrolidin-1-ylazetidin-1-yl)pyrimidin-2,4-diamin, N4-bicyclo[1.1.1]pent-1-yl-6-[(3R)-3-(methylamino)pyrrolidin-1-yl]pyrimidin-2,4-diamin, 6-[3-methyl-3-(methylamino)azetidin-1-yl]-N4-propylpyrimidin-2,4-diamin, N4-(2,2-dimethylpropyl)-6-(hexahydropyrrolo[1,2-a]pyrazin-2(1H)-yl)pyrimidin-2,4- diamin, N4-(2,2-dimethylpropyl)-6-(3-pyrrolidin-1-ylazetidin-1-yl)pyrimidin-2,4-diamin, N4-(2,2-dimethylpropyl)-6-[3-(isopropylamino)azetidin-1-yl]pyrimidin-2,4-diamin, N4-(ferf-butyl)-6-[(3R)-3-(methylamino)pyrrolidin-1-yl]pyrimidin-2,4-diamin, 6-[(3R)-3-(methylamino)pyrrolidin-1-yl]-N4-(1-methylcyclopropyl)pyrimidin-2,4-diamin, N4-(ferf-butyl)-6-[(4aS*,7aS*)-octahydro-6H-pyrrolo[3,4-b]pyridin-6-yl]pyrimidin-2,4- diamin, N4-(2,2-dimethylpropyl)-6-piperazin-1-ylpyrimidin-2,4-diamin, N4-(2,2-dimethylpropyl)-6-[3-(methylamino)azetidin-1-yl]pyrimidin-2,4-diamin- hydrochlorid, N4-(2,2-dimethylpropyl)-6-[(3aR*,7aS*)-octahydro-5H-pyrrolo[3,2-c]pyridin-5- yl]pyrimidin-2,4-diamin, 6-piperazin-1-yl-N4-propylpyrimidin-2,4-diamin, N4-(cyclopropylmethyl)-6-[(4aR,7aR)-octahydro-6H-pyrrolo[3,4-b]pyridin-6-yl]pyrimidin- 2.4- diamin, N4-(2,2-dimethylpropyl)-6-[(4aS,7aS)-octahydro-6H-pyrrolo[3,4-b]pyridin-6-yl]pyrimidin- 2.4- diamin, N4-isopropyl-6-[(4aS,7aS)-octahydro-6H-pyrrolo[3,4-b]pyridin-6-yl]pyrimidin-2,4- diamin, 4-[3-(methylamino)azetidin-1-yl]-6-(4-methylpiperidin-1-yl)pyrimidin-2-amin, N4-(cyclopentylmethyl)-6-[(3R)-3-(methylamino)pyrrolidin-1-yl]pyrimidin-2,4-diamin, N4-cyclobutyl-6-[(4aS,7aS)-octahydro-6H-pyrrolo[3,4-b]pyridin-6-yl]pyrimidin-2,4- diamin, 6-[(3R)-3-(methylamino)pyrrolidin-1-yl]-N4-propylpyrimidin-2,4-diamin, og N4-ethyl-6-(4-methyl-1,4-diazepan-1-yl)pyrimidin-2,4-diamin.
6. Forbindelse ifølge krav 1, eller et farmaceutisk og/eller veterinært acceptabelt salt eller solvat deraf, hvilken forbindelse er A/*-(cyclopropylmethyl)-6-[(3R)-3-(methylamino)pyrrolidin-1-yl]pyrimidin-2,4-diamin.
7. Salt ifølge krav 6, hvilke salt er /^-(cyclopropylmethylJ-e-IXSRJ-S-imethylamino)-pyrrolidin-1-yl]pyrimidin-2,4-diamin-L-tartrat.
8. Farmaceutisk sammensætning omfattende en forbindelse ifølge ethvert af kravene 1 til 6, eller et farmaceutisk og/eller veterinært acceptabelt salt eller solvat deraf, eller saltet ifølge krav 7, sammen med et farmaceutisk acceptabelt excipiens.
9. Forbindelse ifølge ethvert af kravene 1 til 6 eller et farmaceutisk og/eller veterinært acceptabelt salt eller solvat deraf, eller saltet ifølge krav 7, til anvendelse som et medikament.
10. Anvendelse af en forbindelse ifølge ethvert af kravene 1 til 6 eller et farmaceutisk og/eller veterinært acceptabelt salt eller solvat deraf, eller saltet ifølge krav 7, til fremstilling af et medikament til behandling af en sygdom valgt blandt inflammatoriske sygdomme, respiratoriske sygdomme (eksempelvis voksen åndenødssyndrom, akut åndenødssyndrom, bronkitis, kronisk bronkitis, kronisk obstruktiv lungesygdom, cystisk fibrose, astma, emphysem, rhinitis, kronisk sinusitis), allergi; allergi-inducerede luftvejsreaktioner, allergisk rhinitis, viral rhinitis, ikke-allergisk rhinitis, vedvarende og årstidsbestemt rhinitis, nasal tilstopning, allergisk tilstopning, kvindelig og mandelig seksuel dysfunktion, hudsygdomme såsom dermatitis og psoriasis, hjertedysfunktioner såsom myokardial iskæmi og arrythmi, sygdomme i mave-tarmkanalen såsom inflammatorisk tarmsygdom, Crohn's sygdom og colitis ulcerosa, cancer, rheumatoid arthritis, hypotension, smerte og overaktive blæretilstande.
11. Forbindelse ifølge ethvert af kravene 1 til 6 eller et farmaceutisk og/eller veterinært acceptabelt salt eller solvat deraf, eller saltet ifølge krav 7, til anvendelse ved behandling af en sygdom valgt blandt inflammatoriske sygdomme, respiratoriske sygdomme (eksempelvis voksen åndenødssyndrom, akut åndenødssyndrom, bronkitis, kronisk bronkitis, kronisk obstruktiv lungesygdom, cystisk fibrose, astma, emphysem, rhinitis, kronisk sinusitis), allergi; allergi-inducerede luftvejsreaktioner, allergisk rhinitis, viral rhinitis, ikke-allergisk rhinitis, vedvarende og årstidsbestemt rhinitis, nasal tilstopning, allergisk tilstopning, kvindelig og mandelig seksuel dysfunktion, hudsygdomme såsom dermatitis og psoriasis, hjerte-dysfunktioner såsom myokardial iskæmi og arrythmi, sygdomme i mave-tarmkanalen såsom inflammatorisk tarmsygdom, Crohn's sygdom og colitis ulcerosa, cancer, rheumatoid arthritis, hypotension, smerte og overaktive blæretilstande.
12. Fremgangsmåde til fremstilling af en forbindelse ifølge ethvert af kravene 1 til 6, omfattende følgende trin: (a) omsætning afen forbindelse af formlen III
med en amin HN(R1)(R4) for tilvejebringelse af en forbindelse af formlen II
efterfulgt af omsætning med en amin HN(R2)(R3) for tilvejebringelse af en forbindelse af formlen I; eller (b) omsætning af en forbindelse af formlen III
med en amin HN(R2)(R3) for tilvejebringelse af en forbindelse af formlen IV
efterfulgt af omsætning med en amin HN(R1)(R4) for tilvejebringelse af en forbindelse af form len I; hvor X og Y er fraspaltelige grupper og R1, R2, R3, R4, R5 og R8 er som defineret i krav 1.
13. Kombination af en forbindelse ifølge ethvert af kravene 1 til 6, eller et farmaceutisk acceptable salt eller solvat deraf, eller saltet ifølge krav 7, med andre terapeutiske midler valgt blandt: • histamin Hi receptor-antagonister, især loratidin, desloratidin, fexofenadin og cetirizin • histamin H3 receptor-antagonister • histamin H2 receptor-antagonister • leukotrien-antagonister, inkl. antagonister for LTB4, LTC4, LTD4, og LTE4; eksempelvis montelukast • phosphodiesterase-inhibitorer, inkl. PDE3 inhibitorer, PDE4 inhibitorer, PDE5 inhibitorer, PDE7 inhibitorer og inhibitorer for to eller flere phosphodiesteraser, såsom duale PDE3/PDE4 inhibitorer • neurotransmitter-genoptagelses-inhibitorer, isærfluoxetin, setralin, paroxetin, ziprasidon • 5-lipoxygenaser (5-LO) inhibitorer eller 5-lipoxygenase-aktiverende protein (FLAP) antagonister • ar og a2-adrenoceptor-agonist-vasokonstriktor-sympathomimetiske midler til dekongestant anvendelse • muscarin M3 receptor-antagonister eller antikolinergiske midler • 32-adrenoceptor-agon ister • dobbeltvirkende β2/Μ3 midler • xanthiner, såsom theophyllin og aminophyllin • ikke-steroide anti-inflammatoriske midler, såsom natriumcromoglycat og nedocromil-natrium • ketotifen • COX-1 inhibitorer (NSAID'er) og COX-2 selektive inhibitorer • orale eller inhalerede glucocorticosteroider • monoklonale antistoffer, som er aktive imod endogene inflammatoriske elementer • anti-tumornecrosefaktor (anti-TNF-a)-midler • adhæsionsmolekyleinhibitorer, inkl. VLA-4-antagonister • kinin-Br og B2-receptor-antagonister • immunosuppressive midler • inhibitorer for matrix-metalloproteaser (MMP'er) • tachykinin ΝΚι, NK2 og NK3 receptor-antagonister • elastase-inhibitorer • adenosin A2a receptor-agonister • inhibitorer for urokinase • forbindelser, som fungerer på dopamin-receptorer, eksempelvis D2-agonister • modulatorerfor NFKb banen, eksempelvis IKK-inhibitorer • midler, som kan klassificeres som mucolytika eller anti-tussiva • antibiotika • modulatorerforcytokin-signaleringsveje, såsom p38 MAP kinase-inhibitorer, syk tyrosin-kinase-inhibitorer eller JAK kinase-inhibitorer • modulatorerfor prostaglandin-vejene, inkl. inhibitorer for H-PDGS og antagonister for DP-1 og CRTH2 • antagonister for kemokinreceptorer CXCR1 og CXCR2 • antagonister for kemokinreceptorer CCR3, CCR4 og CCR5 • inhibitorer for cytosolisk og opløselige phospholipaser A2 (CPLA2 og SPLA2) • prostaglandin D2 receptor-antagonister (DP1 og CRTH2) • inhibitorer for prostaglandin D syntase (PGDS) • inhibitorer for phosphoinositid-3-kinase, • HDAC inhibitorer, • p38 inhibitorer og/eller • CXCR2 antagonister.
DK06831747.8T 2005-12-20 2006-12-07 Pyrimidinderivater DK1966162T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US75261205P 2005-12-20 2005-12-20
PCT/IB2006/003668 WO2007072163A2 (en) 2005-12-20 2006-12-07 Pyrimidine derivatives

Publications (1)

Publication Number Publication Date
DK1966162T3 true DK1966162T3 (da) 2017-06-19

Family

ID=38124887

Family Applications (1)

Application Number Title Priority Date Filing Date
DK06831747.8T DK1966162T3 (da) 2005-12-20 2006-12-07 Pyrimidinderivater

Country Status (37)

Country Link
US (1) US7943628B2 (da)
EP (1) EP1966162B1 (da)
JP (1) JP5166280B2 (da)
KR (2) KR101152719B1 (da)
CN (1) CN101341134B (da)
AP (1) AP2008004486A0 (da)
AR (1) AR058557A1 (da)
AU (1) AU2006327876B2 (da)
BR (1) BRPI0620201A2 (da)
CA (1) CA2634018C (da)
CR (1) CR10061A (da)
CY (1) CY1118987T1 (da)
DK (1) DK1966162T3 (da)
DO (1) DOP2006000288A (da)
EA (1) EA200801381A1 (da)
EC (1) ECSP088559A (da)
ES (1) ES2628482T3 (da)
GT (1) GT200600518A (da)
HK (1) HK1120269A1 (da)
HR (1) HRP20170896T1 (da)
HU (1) HUE034650T2 (da)
IL (1) IL191432A (da)
LT (1) LT1966162T (da)
MA (1) MA30082B1 (da)
ME (1) ME00004B (da)
NL (1) NL2000323C2 (da)
NO (1) NO341075B1 (da)
PE (1) PE20070848A1 (da)
PL (1) PL1966162T3 (da)
PT (1) PT1966162T (da)
RS (2) RS56102B1 (da)
SI (1) SI1966162T1 (da)
TN (1) TNSN08269A1 (da)
TW (1) TW200732306A (da)
UY (1) UY30045A1 (da)
WO (1) WO2007072163A2 (da)
ZA (1) ZA200805294B (da)

Families Citing this family (55)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2009507896A (ja) * 2005-09-13 2009-02-26 パラウ・フアルマ・ソシエダツド・アノニマ ヒスタミンｈ４受容体活性の調節剤としての２−アミノピリミジン誘導体
NL2000323C2 (nl) * 2005-12-20 2007-11-20 Pfizer Ltd Pyrimidine-derivaten.
WO2007120690A2 (en) * 2006-04-10 2007-10-25 Janssen Pharmaceutica N.V. Combination histamine h1r and h4r antagonist therapy for treating pruritus
AU2007287428B2 (en) 2006-08-24 2011-08-11 Astrazeneca Ab Morpholino pyrimidine derivatives useful in the treatment of proliferative disorders
US7985745B2 (en) * 2006-10-02 2011-07-26 Abbott Laboratories Method for pain treatment
TW200904437A (en) 2007-02-14 2009-02-01 Janssen Pharmaceutica Nv 2-aminopyrimidine modulators of the histamine H4 receptor
US20080217501A1 (en) * 2007-02-14 2008-09-11 Chad Jensen Power a-frame
US8637528B2 (en) 2007-03-27 2014-01-28 Omeros Corporation Use of PDE7 inhibitors for the treatment of movement disorders
JP5508260B2 (ja) 2007-07-09 2014-05-28 アストラゼネカ アクチボラグ ｍＴＯＲキナーゼおよび／またはＰ１３Ｋに関連する病気に用いられるモルホリノピリミジン誘導体
WO2009068512A1 (en) * 2007-11-30 2009-06-04 Palau Pharma, S. A. 2 -amino-pyrimidine derivatives as histamine h4 antagonists
AR069813A1 (es) * 2007-12-19 2010-02-17 Palau Pharma Sa Derivados de 2- amino-pirimidina, una composicion farmaceutica, un metodo de preparacion del compuesto y uso del mismo para preparar un medicamento
US8278313B2 (en) * 2008-03-11 2012-10-02 Abbott Laboratories Macrocyclic spiro pyrimidine derivatives
AU2009244897B2 (en) 2008-04-16 2014-11-13 Alexion Pharmaceuticals, Inc. 2, 6-diamino- pyrimidin- 5-yl-carboxamides as syk or JAK kinases inhibitors
US8138339B2 (en) 2008-04-16 2012-03-20 Portola Pharmaceuticals, Inc. Inhibitors of protein kinases
EA018198B1 (ru) * 2008-06-12 2013-06-28 Янссен Фармацевтика Нв Диаминопиридиновые, пиримидиновые и пиридазиновые модуляторы гистаминового рецептора h
US8436008B2 (en) 2008-12-22 2013-05-07 Incyte Corporation Substituted heterocyclic compounds
EP2201982A1 (en) 2008-12-24 2010-06-30 INSERM (Institut National de la Santé et de la Recherche Médicale) Histamine H4 receptor antagonists for the treatment of vestibular disorders
US8349852B2 (en) 2009-01-13 2013-01-08 Novartis Ag Quinazolinone derivatives useful as vanilloid antagonists
IT1393337B1 (it) 2009-03-06 2012-04-20 Italiana Sint Spa Sintesi di (4as, 7as)-ottaidro-1h-pirrolo[3,4-b]piridina
US8481732B2 (en) 2009-03-20 2013-07-09 Incyte Corporation Substituted heterocyclic compounds
FR2945533B1 (fr) * 2009-05-12 2011-05-27 Sanofi Aventis Derives de cyclopenta°c!pyrrolyl-alkylcarbamates d'heterocycles a 5 chainons, leur preparation et leur application en therapeutique
WO2011051452A1 (en) 2009-10-29 2011-05-05 Palau Pharma, S.A. N-containing heteroaryl derivatives as jak3 kinase inhibitors
AR079725A1 (es) 2009-12-23 2012-02-15 Palau Pharma Sa Derivados de aminoalquilpirimidina como antagonistas del receptor h4
WO2011092293A2 (en) 2010-02-01 2011-08-04 Novartis Ag Cyclohexyl amide derivatives as crf receptor antagonists
US20120295942A1 (en) 2010-02-01 2012-11-22 Nicholas James Devereux Pyrazolo[5,1b]oxazole Derivatives as CRF-1 Receptor Antagonists
JP5748777B2 (ja) 2010-02-02 2015-07-15 ノバルティス アーゲー Ｃｒｆ受容体アンタゴニストとしてのシクロヘキシルアミド誘導体
JP5607241B2 (ja) 2010-05-21 2014-10-15 ケミリア・エービー 新規ピリミジン誘導体
SA111320519B1 (ar) 2010-06-11 2014-07-02 Astrazeneca Ab مركبات بيريميدينيل للاستخدام كمثبطات atr
AU2012230229A1 (en) 2011-03-24 2013-10-10 Noviga Research Ab Novel pyrimidine derivatives
JP6039683B2 (ja) 2011-11-23 2016-12-07 ポートラ ファーマシューティカルズ， インコーポレイテッド ピラジンキナーゼ阻害剤
US10213421B2 (en) 2012-04-04 2019-02-26 Alkahest, Inc. Pharmaceutical formulations comprising CCR3 antagonists
WO2013152717A1 (zh) 2012-04-10 2013-10-17 上海昀怡健康管理咨询有限公司 稠合嘧啶类化合物，其制备方法，中间体，组合物和应用
AU2013263420A1 (en) * 2012-05-15 2015-01-22 Calasia Pharmaceuticals, Inc. Pyrimidine diamine derivatives as inhibitors of cytosolic Hsp90
FR2990859B1 (fr) * 2012-05-24 2014-05-23 Gaetan Terrasse Utilisation d'une molecule h4 agoniste pour le traitement de la mucoviscidose
HUE039713T2 (hu) 2012-06-08 2019-02-28 Sensorion H4 receptor inhibitorok tinnitus kezelésére
US9974759B2 (en) 2013-05-31 2018-05-22 Indiana University Research And Technology Corporation Beta 2 adrenoceptor antagonists for treating orthostatic hypotension
US9745321B2 (en) 2013-09-30 2017-08-29 Shanghai Yingli Pharmaceutical Co., Ltd Fused pyrimidine compound, intermediate, preparation method therefor, and composition and application thereof
CN104903312B (zh) * 2013-10-07 2019-01-29 卡德门企业有限公司 Rho激酶抑制剂
SG11201602446VA (en) 2013-10-16 2016-05-30 Shanghai Yingli Pharm Co Ltd Fused heterocyclic compound, preparation method therefor, pharmaceutical composition, and uses thereof
WO2015090224A1 (zh) * 2013-12-20 2015-06-25 中国人民解放军军事医学科学院毒物药物研究所 新型哌啶氨甲酰类化合物、制备方法及其用途
SG11201700777VA (en) 2014-08-04 2017-02-27 Nuevolution As Optionally fused heterocyclyl-substituted derivatives of pyrimidine useful for the treatment of inflammatory, metabolic, oncologic and autoimmune diseases
NO2721710T3 (da) 2014-08-21 2018-03-31
JP2018505197A (ja) * 2015-02-13 2018-02-22 メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツングＭｅｒｃｋ Ｐａｔｅｎｔ Ｇｅｓｅｌｌｓｃｈａｆｔ ｍｉｔ ｂｅｓｃｈｒａｅｎｋｔｅｒ Ｈａｆｔｕｎｇ がんの処置において使用するためのピリミジン誘導体
TW201729810A (zh) * 2015-10-26 2017-09-01 札爾科製藥公司 嘧啶組成物、其超純組成物及鹽類、製造彼之方法、及使用彼於治療組織胺h4受體(h 4 )仲介之疾病與病情之方法
JP6985388B2 (ja) * 2016-07-29 2021-12-22 ラプト・セラピューティクス・インコーポレイテッド ケモカイン受容体調節剤及びそれの使用
EP3510029A4 (en) * 2016-09-07 2020-03-11 The Regents of The University of California ALLOSTERIC CORTICOTROPIN RELEASING FACTOR-1 (CRFR1) ANTAGONISTS TO REDUCE P-TAU AND IMPROVE THE COGNITION
US10342786B2 (en) 2017-10-05 2019-07-09 Fulcrum Therapeutics, Inc. P38 kinase inhibitors reduce DUX4 and downstream gene expression for the treatment of FSHD
PT3691620T (pt) 2017-10-05 2022-10-06 Fulcrum Therapeutics Inc Os inibidores da quinase p38 reduzem a expressão de dux4 e genes a jusante para o tratamento de fshd
GB201817047D0 (en) * 2018-10-19 2018-12-05 Heptares Therapeutics Ltd H4 antagonist compounds
MX2022007265A (es) 2019-12-20 2022-09-09 Nuevolution As Compuestos activos frente a receptores nucleares.
EP4126875A1 (en) 2020-03-31 2023-02-08 Nuevolution A/S Compounds active towards nuclear receptors
US11780843B2 (en) 2020-03-31 2023-10-10 Nuevolution A/S Compounds active towards nuclear receptors
GB202005858D0 (en) * 2020-04-22 2020-06-03 Heptares Therapeutics Ltd H4 Antagonist compounds
US11548874B2 (en) * 2020-05-19 2023-01-10 Florida State University Research Foundation, Inc. Antifibrotic compounds and related methods
CR20230125A (es) 2020-08-14 2023-05-11 Novartis Ag Derivados de espiropiperidinilo sustituidos con heteroarilo y usos farmacéuticos de los mismos

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS60140435A (ja) * 1983-12-28 1985-07-25 Hitachi Ltd 命令処理装置
US5099019A (en) * 1985-09-12 1992-03-24 Upjohn Company Amines useful in producing pharmaceutically active CNS compounds
CA1338012C (en) * 1987-04-27 1996-01-30 John Michael Mccall Pharmaceutically active amines
WO1991006542A1 (en) * 1989-10-25 1991-05-16 The Upjohn Company Pharmaceutically active amino-substituted heteroaryl amines
KR0166088B1 (ko) 1990-01-23 1999-01-15 . 수용해도가 증가된 시클로덱스트린 유도체 및 이의 용도
US5376645A (en) 1990-01-23 1994-12-27 University Of Kansas Derivatives of cyclodextrins exhibiting enhanced aqueous solubility and the use thereof
HUT64323A (en) * 1992-06-09 1993-12-28 Richter Gedeon Vegyeszet Process for production new piperazinyl-bis(alkyl-amino)-pyrimidine derivatives
HU212308B (en) * 1992-06-09 1996-05-28 Richter Gedeon Vegyeszet Process for producing novel pregnane steroids and pharmaceutical compositions containing the same
GB9518953D0 (en) 1995-09-15 1995-11-15 Pfizer Ltd Pharmaceutical formulations
WO2000035298A1 (en) 1996-11-27 2000-06-22 Wm. Wrigley Jr. Company Chewing gum containing medicament active agents
GB9711643D0 (en) 1997-06-05 1997-07-30 Janssen Pharmaceutica Nv Glass thermoplastic systems
WO2001047921A1 (en) 1999-12-28 2001-07-05 Pharmacopeia, Inc. Pyrimidine and triazine kinase inhibitors
WO2002072548A2 (en) 2001-03-09 2002-09-19 Ortho-Mcneil Pharmaceutical, Inc. Heterocyclic compounds and their use as histamine h4 ligands.
US6924290B2 (en) * 2002-01-23 2005-08-02 Bayer Pharmaceuticals Corporation Rho-kinase inhibitors
DE10226943A1 (de) * 2002-06-17 2004-01-08 Bayer Ag Phenylaminopyrimidine und ihre Verwendung
ATE325125T1 (de) * 2002-09-06 2006-06-15 Janssen Pharmaceutica Nv Thienopyrrolyl und furanopyrrolyl verbindungen und deren verwendung als histamin h4 rezeptor liganden
WO2004039796A1 (de) * 2002-10-28 2004-05-13 Bayer Healthcare Ag Heteroaryloxy-substituierte phenylaminopyrimidine als rho-kinaseinhibitoren
WO2004052862A1 (ja) * 2002-12-10 2004-06-24 Ono Pharmaceutical Co., Ltd. 含窒素複素環化合物およびその医薬用途
US20050014753A1 (en) * 2003-04-04 2005-01-20 Irm Llc Novel compounds and compositions as protein kinase inhibitors
EP1505064A1 (en) * 2003-08-05 2005-02-09 Bayer HealthCare AG 2-Aminopyrimidine derivatives
US7223759B2 (en) * 2003-09-15 2007-05-29 Anadys Pharmaceuticals, Inc. Antibacterial 3,5-diaminopiperidine-substituted aromatic and heteroaromatic compounds
WO2005054239A1 (en) * 2003-12-05 2005-06-16 Bayer Healthcare Ag 2-aminopyrimidine derivatives
JP2009507896A (ja) * 2005-09-13 2009-02-26 パラウ・フアルマ・ソシエダツド・アノニマ ヒスタミンｈ４受容体活性の調節剤としての２−アミノピリミジン誘導体
EP1767537A1 (en) 2005-09-21 2007-03-28 Cellzome (UK) Ltd. Pyrimidine compounds for the treatment of inflammatory disorders
NL2000323C2 (nl) * 2005-12-20 2007-11-20 Pfizer Ltd Pyrimidine-derivaten.

Also Published As

Publication number Publication date
CY1118987T1 (el) 2018-01-10
NL2000323A1 (nl) 2007-06-21
EA200801381A1 (ru) 2009-02-27
NO341075B1 (no) 2017-08-21
PL1966162T3 (pl) 2017-09-29
KR20080069260A (ko) 2008-07-25
RS20080278A (en) 2009-07-15
PE20070848A1 (es) 2007-09-10
AP2008004486A0 (en) 2008-06-30
ME00004B (me) 2010-06-10
EP1966162B1 (en) 2017-03-15
LT1966162T (lt) 2017-07-10
NL2000323C2 (nl) 2007-11-20
BRPI0620201A2 (pt) 2011-11-01
HUE034650T2 (hu) 2018-02-28
CR10061A (es) 2008-07-17
CA2634018A1 (en) 2007-06-28
WO2007072163A3 (en) 2007-10-04
CN101341134B (zh) 2013-05-01
AR058557A1 (es) 2008-02-13
GT200600518A (es) 2007-07-23
RS56102B1 (sr) 2017-10-31
ZA200805294B (en) 2009-11-25
MA30082B1 (fr) 2008-12-01
EP1966162A2 (en) 2008-09-10
ES2628482T3 (es) 2017-08-03
US20070185075A1 (en) 2007-08-09
US7943628B2 (en) 2011-05-17
JP2009520019A (ja) 2009-05-21
KR101152719B1 (ko) 2012-06-18
DOP2006000288A (es) 2007-07-31
HK1120269A1 (en) 2009-03-27
NO20082980L (no) 2008-08-28
CA2634018C (en) 2013-10-08
WO2007072163A2 (en) 2007-06-28
TW200732306A (en) 2007-09-01
MEP0508A (xx) 2010-02-10
AU2006327876A1 (en) 2007-06-28
ECSP088559A (es) 2008-07-30
HRP20170896T1 (hr) 2017-09-08
IL191432A (en) 2014-08-31
SI1966162T1 (sl) 2017-07-31
AU2006327876B2 (en) 2010-12-16
JP5166280B2 (ja) 2013-03-21
KR20120025010A (ko) 2012-03-14
TNSN08269A1 (en) 2009-10-30
PT1966162T (pt) 2017-06-02
UY30045A1 (es) 2007-07-31
CN101341134A (zh) 2009-01-07

Similar Documents

Publication Publication Date Title
DK1966162T3 (da) Pyrimidinderivater
TWI591067B (zh) 吡唑并吡啶及吡唑并嘧啶
NL1029016C2 (nl) Tetrahydronafthyridinederivaten.
JP7208142B2 (ja) Ｒｈｏキナーゼ阻害剤としてのチロシンアミド誘導体
KR100549152B1 (ko) 피라졸로[4,3-ｄ]피리미딘 유도체
ES2314690T3 (es) Derivados de triazolopiridinilsulfanilo como inhibidores de la map quinasa p38.
US20190119245A1 (en) Indole carboxamide compounds
JP2020506899A (ja) Ｍａｇｌ阻害薬としての１，１，１−トリフルオロ−３−ヒドロキシプロパン−２−イルカルバマート誘導体
JP2017519030A (ja) 糖尿病、肥満症及び炎症性腸疾患の治療又は予防に有用な１，３−置換２−アミノインドール誘導体及び類似体
MX2008008283A (en) Pyrimidine derivatives
WO2023194964A1 (en) Fused pyridazine derivatives as nlrp3 inhibitors
CN116262750A (zh) 一种芳杂环类化合物及其制备方法和用途
JP2024504824A (ja) 芳香族複素環化合物及びその製造方法と用途
EP1671972A1 (en) Octahydropyrrolo[3,4-c]pyrrole derivatives
JP2007509127A (ja) ホスホジエステラーゼ−４阻害剤としてのアザベンゾジアゼピン